Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis.
about
Immune therapy in type 1 diabetes mellitusChanges in GAD65Ab-specific antiidiotypic antibody levels correlate with changes in C-peptide levels and progression to islet cell autoimmunityVaccination against type 1 diabetes.Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth studyType 1 diabetes as a model for prediction and diagnosis.Spontaneous complete remission of type 1 diabetes mellitus in an adult - review and case report.Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds.Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes.New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes.Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update.The C-peptide response to a standard mixed meal in a group of Brazilian type 1 diabetic patients.Long-term sustained autoimmune response to beta cell specific zinc transporter (ZnT8, W, R, Q) in young adult patients with preserved beta cell function at diagnosis of diabetes.Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr.[Pancreatic function assessment in type 1 diabetes mellitus patients according to disease duration].Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls.Implicações clínicas da persistência de anti-GAD positivo e peptídeo C detectável em pacientes com diabetes melito tipo 1 de longa duração
P2860
Q28282846-E03A0D55-0F86-4EF1-A2AE-D93FA1F353A4Q34262463-22AFF284-0AD7-48D5-BBF4-D707C37EF7A1Q35004343-C468399F-0CD2-4E9E-B7F4-B7894B50956AQ35822130-278672C2-FC8A-4EB5-9CC9-47F90E1002B8Q35934762-50AEC1B5-BA22-4F0B-B6AD-B01419374D18Q36181700-72AC1EEE-A675-4A21-AE34-D49816F5A7DEQ36555009-4410D56E-5BED-4FEB-A0B3-F5A5E5015D82Q36560230-12763125-505D-4A84-AF62-072BB2298A82Q36714327-41EDF848-4547-4944-A11A-DFF07E56BBEAQ37662519-016B0CD6-FCFB-4BB9-8CC1-73DD1891E503Q42451970-DEF64EF1-4DE7-4C63-A8AD-A1D8BF02206BQ44713976-1E1231C4-04B2-462A-A55B-6B796A410ACFQ46443792-C855E212-ED55-4B7B-8276-DEE85A7BAAAAQ51427531-9DF135C7-C545-4E46-A58E-46A0861B7992Q52798088-F944CB3F-7A83-4FC8-981A-0DC1A9F46E93Q57831167-738A247D-4C2B-4158-BE98-DB92DABF9379
P2860
Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Factors influencing the magnit ...... from their clinical diagnosis.
@en
Factors influencing the magnit ...... from their clinical diagnosis.
@nl
type
label
Factors influencing the magnit ...... from their clinical diagnosis.
@en
Factors influencing the magnit ...... from their clinical diagnosis.
@nl
prefLabel
Factors influencing the magnit ...... from their clinical diagnosis.
@en
Factors influencing the magnit ...... from their clinical diagnosis.
@nl
P2093
P356
P1433
P1476
Factors influencing the magnit ...... from their clinical diagnosis.
@en
P2093
A Lernmark
G Dahlquist
G Sundkvist
M Wallensteen
P2888
P304
P356
10.1007/BF00278749
P577
1988-09-01T00:00:00Z